Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ ...

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 ...

Zasocitinib is also being evaluated in a head-to-head study against Bristol Myers Squibb’s Sotyktu (deucravacitinib) in ...

(GLOBE NEWSWIRE) -- (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been ...

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, ...

In a combined network meta-analysis, infliximab and adalimumab had the greatest risk for serious infection in patients with plaque psoriasis.

Appoints accomplished commercial leader Chris Martin to its Board of Directors ...

PsO is a systemic inflammatory disease that presents not only as scaly skin lesions, erythema, and itching but also affects ...

Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug ILUMYA in India for the treatment of moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA ...

Icotrokinra, a novel oral interleukin (IL)-23 inhibitor, provided a level of response in moderate-to-severe plaque psoriasis that is similar to that previously reported with injectable biologics, ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

About Plaque Psoriasis Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is ...